Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBT (2016 - 2025)

Historic EBT for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$44.5 million.

  • Coherus Oncology's EBT rose 647.49% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.0 million, marking a year-over-year increase of 12439.88%. This contributed to the annual value of $28.5 million for FY2024, which is 11196.41% up from last year.
  • Coherus Oncology's EBT amounted to -$44.5 million in Q3 2025, which was up 647.49% from -$44.9 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's EBT ranged from a high of $197.8 million in Q4 2024 and a low of -$172.9 million during Q1 2021
  • Moreover, its 5-year median value for EBT was -$47.6 million (2024), whereas its average is -$48.8 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 57376.25% in 2021, then skyrocketed by 34833.72% in 2024.
  • Over the past 5 years, Coherus Oncology's EBT (Quarter) stood at -$45.7 million in 2021, then decreased by 28.75% to -$58.9 million in 2022, then plummeted by 35.3% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then plummeted by 122.51% to -$44.5 million in 2025.
  • Its EBT stands at -$44.5 million for Q3 2025, versus -$44.9 million for Q2 2025 and -$47.4 million for Q1 2025.